-- Successful completion of first trial phase enables continued pivotal trial of FemBloc, the only non-surgical permanent birth control, toward U.S. FDA approval -- -- $12 million senior secured convertible notes for total potential proceeds of $58 million, if all warrants are exercised for cash, reflecting strong investor confidence in Femasys’ women’s health mission -- ATLANTA, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator making fertility and non-surgical ...

BEIJING, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Global Mofy AI Limited (the “Company” or “Global Mofy”) (Nasdaq: GMM), a generative AI-driven technology solutions provider engaged in virtual content production and the development of 3D digital assets for use in the broader digital content industry, today announced that representatives from the Chinese Academy of International Trade and Economic Cooperation under the Ministry of Commerce (“CAITEC”) and the Commercial Circulation Promotion Division of the Chaoyang ...

Global evidence and real-world data demonstrate the clinical, operational, and economic impact of AVITA Medical’s RECELL System across wound types and patient populationsVALENCIA, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (“AVITA Medical,” or the “Company”), a leading therapeutic acute wound care company, today announced two podium presentations at the 2025 Southern Region Burn Conference (SRBC) that collectively underscore the clinical and economic value of the ...

FORT MYERS, Fla., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Alico Inc., (“Alico” or the “Company”) (Nasdaq: ALCO) a Southwest Florida-based agribusiness and land management company with over 125 years of experience, has announced a strategic partnership with the Florida Department of Transportation (“FDOT”) and its construction contractor to design and construct a wildlife underpass as part of a planned expansion of State Road 82 to four lanes in Collier County. The wildlife underpass will align with a proposed wil ...

TORONTO, Nov. 03, 2025 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) a premier artificial intelligence (AI) company that is transforming clinical trials with AI powered precision analytics in the pharmaceutical industry, today announced that it has signed a new contract with a leading biopharmaceutical company to apply its NetraAI platform to a Phase 3 clinical trial of a novel psychiatric medicine. This represents continued industry p ...

TORONTO, Nov. 03, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTCQB:MDXXF), a biotechnology company focused on the research, development, and manufacturing of novel MDXX class molecules (including its LaNeo™ MDMA), is pleased to announce that it has filed its final short form base shelf prospectus (the “Prospectus”) to provide the Company with the flexibility to take advantage of financing opportunities and favourable market conditions, if and when need ...

Combined entity poised to reshape digital payments, asset management, RWA tokenization, and digital media by applying Brag House's proven model to a global stage.NEW YORK and MIAMI, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Brag House Holdings, Inc. (NASDAQ: TBH) ("Brag House") and its merger partner, House of Doge Inc. ("House of Doge"), the official corporate arm of the Dogecoin Foundation, today provided a strategic update on their definitive merger agreement. The merger is set to create a comprehensive financia ...

Signed 20 license agreements with new customers in key growth areas since separationPaid down $11 million of debt in the third quarter, bringing total debt repayment to $312 million since separationFiled patent infringement litigation against AMD SAN JOSE, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Adeia Inc. (Nasdaq: ADEA) (the “Company” or “Adeia”) today announced financial results for the third quarter ended September 30, 2025. “Third quarter revenue of $87.3 million was in line with our expectations for ...

诉讼核心信息 - 公司已向美国德克萨斯州西区地方法院提起针对AMD的专利侵权诉讼 [1] - 诉讼涉及公司半导体知识产权组合中的10项专利 包括7项混合键合技术专利和3项先进工艺节点技术专利 [2] 公司立场与背景 - 公司采取法律行动旨在保护其知识产权及在基础半导体技术上的投资 并指出AMD产品广泛使用了其专利技术 [2] - 公司在提起诉讼前曾尝试通过非诉讼方式达成双方同意的解决方案但未果 [2] - 公司对诉讼结果持乐观态度 但仍对达成公平合理的安排持开放态度 [3] - 公司及其前身企业过去40年持续研发投入 拥有全球最大的知识产权组合之一 包含超过13000项全球专利资产 [3] 公司业务概览 - 公司是一家领先的研发与知识产权授权企业 专注于推动媒体和半导体行业的创新技术应用 [4] - 公司的基础创新是塑造未来数字娱乐和电子产品的技术解决方案的核心 [4] - 公司的知识产权组合为全球数百万用户日常使用的连接设备提供支持 [4]

NEEDHAM, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that Paul Peter Tak, M.D., Ph.D., FMedSci, Candel’s President and Chief Executive Officer, will present at the Jefferies Global Healthcare Conference, being held on November 17-20, 2025 in London, United Kingdom. Presentation Details: Date: Tues ...